Clinical Trials Browser

Breast Neoplasms

Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Endometrial Neoplasms

Malignant Female Reproductive System Neoplasm

Neoplasm Metastasis

Breast Neoplasms

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

Breast Neoplasms, Inflammatory Breast Neoplasms

Stomach Neoplasms

Breast Neoplasms

Breast Neoplasms

Neoplasm Metastasis

Neoplasm Metastasis

Ependymoma, Meningioma, Neuroma, Acoustic, Neurofibromatosis 2

Brain Neoplasms, Breast Neoplasms

Disease, Leukemia, Lymphoma, Recurrence, Central Nervous System Neoplasms

Glioblastoma

Breast Neoplasms, Triple Negative Breast Neoplasms

Gastrointestinal Neoplasms, Stomach Neoplasms

Breast Neoplasms

Carcinoma, Lobular

Breast Cancer With Brain Metastasis

Breast Neoplasms

Breast Neoplasms

HER2-positive Breast Cancer

Breast Neoplasms

Ovarian Neoplasms

Biliary Tract Neoplasms

Clinical Trials

Capecitabine 7/7 Schedule With Neratinib in Patients With Metastatic HER2-Positive Breast Cancer

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial)

Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 Gene

Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers

I-SPY

Neratinib and Paclitaxel With or Without Pertuzumab and Trastuzumab Before Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Breast Cancer

Neratinib In Combination With Chemotherapy/Trastuzumab/Pembrolizumab In HER2 Gastroesophageal Cancer

HKI-272 for HER2-Positive Breast Cancer and Brain Metastases

Neratinib +/- Fulvestrant in HER2+, ER+ Metastatic Breast Cancer

GERTRUDE

Neratinib and Everolimus, Palbociclib, or Trametinib in Treating Participants With Refractory and Advanced or Metastatic Solid Tumors With EGFR Mutation/Amplification, HER2 Mutation/Amplification, or HER3/4 Mutation or KRAS Mutation

INTUITT-NF2

Trial of Neratinib Plus Capecitabine in Subjects With HER2-Negative Metastatic Breast Cancer With Brain Metastases and Abnormally Active HER2 Signaling

Safety and Dose Finding Study of Neratinib in Children and Young Adults With Cancer That Has Returned or Not Responded to Treatment

INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)

Neratinib in Combination With Ruxolitinib in Patients With mTNBC

Neratinib and Fam-Trastuzumab Deruxtecan in Advanced Gastro-esophageal Cancer Patients

Adjuvant Trastuzumab Plus Neratinib in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer After Neoadjuvant Trastuzumab Plus Pertuzumab

Neoadjuvant Neratinib in Stage I-III HER2-Mutated Lobular Breast Cancers

THUNDER

ELEANOR

Incidence and Severity of Diarrhea in Patients With HER2 Positive Breast Cancer Treated With Trastuzumab and Neratinib

Neratinib in Extended Adjuvant Treatment for HER2+ Early Breast Cancer With pCR But High-Risk Features: A Hebei Multi-Center Real-World Study

Neratinib and Capmatinib Combination (Phase Ib/II) in Metastatic Breast Cancer and Inflammatory Breast Cancer Patients With Abnormal HER-family and c-Met Pathway Activity as Measured by the CELsignia Signaling Analysis Test

iNNOVATE

SAFIR-ABC10